In-silico study reveals potential antitubercular drug targets unique to Mycobacterium tuberculosis H37Rv

Maurya S., Alhazmi A., Vidyarthi A. S., Jain A., Singh V., Khan F., ...Daha Fazla

MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH, cilt.34, sa.2, ss.71-79, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.23736/s2724-542x.21.02849-2
  • Dergi Adı: MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.71-79
  • Anahtar Kelimeler: Mycobacterium tuberculosis, Proteome, Genes, essential, Gene ontology, IDENTIFICATION
  • Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

BACKGROUND: Developing safe drugs for tuberculosis (TB), is a major challenge due to upsurge in drug resistance, hepatotoxicity, and the presence of Mycobacterium tuberculosis (Mtb) targets orthologs in human and its non-pathogenic host E. coli. Prostaglandin G/H synthase-2 and 30S ribosomal-S12 protein of Mtb show 100 and 48% similarity with human proteins respectively. Thus, targeting these Mtb proteins by p-aminosalicylic acid and streptomycin for the treatment of TB adversely affect human metabolism, and warrants to identify novel and unique drug targets of Mtb.